Replies to post #93955 on Biotech Values

[DewDiligence]

So if a woman has a 1st degree carrier but her own test is negative, I would still ask for copy number variation to be on the safe side.

The BRAC1/2 tests may have implications for male cancers too, although perhaps not to a degree that would justify commercialization.

[Biowatch]

"not even a common knowledge to one skilled in the art."

Which is why I think their basic patent(s) won't/shouldn't be overturned.

This was cutting edge research at the time, something easy to forget after the human genome project and various gene sequencing competitors "did" it all.

At the time, they allegedly warned volunteers that mention of results or participation in the study to healthcare providers might mean they'd be written off as having a pre-existing condition, rather than recognition as people doing their best to minimize future risk for themselves and others and help cure a problem.

That's why "personalized medicine" is still important, as not one gene sequence fits all, and there's lots of research yet to be done.

There are still questions about how much is a "fair" price to charge for the diagnosis, especially as gene sequencing gets cheaper.

In my humble opinion.